Clinical Rheumatology and Related Research
Online ISSN : 2189-0595
Print ISSN : 0914-8760
ISSN-L : 0914-8760
original article
New clinical markers for patients with rheumatoid arthritis
Hiraku KikuchiWataru ShimadaFumihiko HaraYasunori ItohHarutoshi Tsujimoto
Author information
JOURNAL FREE ACCESS

2007 Volume 19 Issue 2 Pages 89-93

Details
Abstract

    C-terminal telopeptides of type 2 collagen (CTX-2) and anticyclic citrullinated peptide antibody (anti-CCP antibody) have recently received considerable attention as new markers of joint destruction in rheumatoid arthritis (RA). In this preliminary study conducted at the Sakai Hospital Kinki University School of Medicine, we measured CTX-2 and anti-CCP antibody levels in 182 RA patients and, as controls, in 69 osteoarthritis (OA) patients and 25 patients with non-inflammatory diseases in order to ascertain whether these two markers can be used as prognostic indicators of joint destruction in RA.
    The CTX-2 levels of RA and OA patients were higher than in the non-inflammatory disease control group and international reference values. In RA patients, the CTX-2 level correlated with the MMP-3 level, indicating age specificity, and was also associated with disease stage.
    The anti-CCP antibody level was high in RA patients. There was no correlation between anti-CCP antibody and other markers including those of inflammation. No anti-CCP antibody was detected in OA patients.

Content from these authors
© 2007 The Japanese Society for Clinical Rheumatology and Related Research
Previous article Next article
feedback
Top